What is SCYNEXIS Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. SCYNEXIS's interest expense for the
three
months ended in Dec. 2023 was $ -0.2 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.1 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. SCYNEXIS's Operating Income for the
three
months ended in Dec. 2023 was $ -23.1 Mil. SCYNEXIS's Interest Expense for the
three
months ended in Dec. 2023 was $ -0.2 Mil.
SCYNEXIS did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
SCYNEXIS Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (NAS:SCYX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
SCYNEXIS's Interest Expense for the
three
months ended in Dec. 2023 was $-0.2 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-23.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $14.7 Mil.
SCYNEXIS's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| SCYNEXIS did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
SCYNEXIS (SCYNEXIS) Business Description
Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Executives
| David C Hastings |
director |
C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
| Brian Philippe Tinmouth |
director |
1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
| Guy Macdonald |
director |
C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139 |
| Ann Hanham |
director |
ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111 |
| Steven C Gilman |
director |
110 HARTWELL AVENUE, LEXINGTON MA 02421 |
| Armando Anido |
director |
80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
| Ivor Macleod |
officer: Chief Financial Officer |
3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634 |
| Scott Sukenick |
officer: General Counsel |
101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302 |
| Marco Taglietti |
director |
C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
| Lawrence R Hoffman |
officer: Interim CFO |
C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087 |
| Christine Coyne |
officer: Chief Commercial Officer |
1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Eric Francois |
officer: Chief Financial Officer |
C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
| Gonzalez David Angulo |
officer: Chief Medical Officer |
C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
SCYNEXIS (SCYNEXIS) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your 